Liquidity & Technicals

Liquidity & Technicals

A £4.4B LSE-listed mid-cap with ~£19M of average daily turnover is institutionally tradable, size-aware — funds up to ~£380M can build a 5% position over five trading days at 20% participation; the system flag of "illiquid" reflects only that 5-day capacity (0.43% of market cap) sits below the methodology's 0.5% reporting tier, not actual market depth. The tape is bearish: price has shed 43% in twelve months and now sits at the 10th percentile of its 52-week range, 23% below the 200-day average, with three death crosses in three years (most recent 2025-10-08) — the market has materially de-rated a business the Numbers tab describes as still growing earnings.

Price snapshot

The critical chart — price vs 50d / 200d (10-year)

Price is decisively below the 200-day. The decade-long uptrend that took the stock from 390p to 911p is broken — current price is back at levels last seen in mid-2017. This is a downtrend, not a sideways consolidation.

Three-year rebased trajectory (no benchmark match)

The data file did not return a usable broad-market or sector benchmark series for this LSE listing, so a like-for-like relative-strength chart is not available. The three-year rebased trajectory below shows the company in absolute terms — the round-trip from 100 → 134 (Sep 2024 peak) → 73 (Apr 2026 trough) → 77 (current) is the entire investment debate compressed onto one line.

The stock spent 30 months (May 2023 to Nov 2025) trending up, then erased every gain in five months. The slope of the decline (Nov 2025 to Mar 2026) is steeper than anything in the prior trend — that asymmetry is what a de-rating event looks like.

Momentum — RSI and MACD (last 18 months)

RSI bottomed at 16.5 on 10 Dec 2025 — a deeply oversold reading rare outside crisis events — and again at 19.1 on 9 Feb 2026. The subsequent rebuild to 60 by mid-April is constructive but the latest print (49.8) is fading back to neutral. The MACD histogram has flipped between positive and negative four times in three months — momentum has stopped going down, but has not yet committed to going up. Near-term read: the bleed has stopped, the recovery has not begun.

Volume, vol-spike days, and realized volatility

The 50-day average ran at ~3M shares through mid-2025, then nearly doubled to ~5M from January 2026 onward. Distribution volume rose as price fell — that is a bearish signature, the opposite of a high-volume bottom on capitulation.

Five of the top ten volume spikes since 2019 cluster at prices above 760p with day-returns near zero — classic distribution prints, where high turnover left the price unchanged because supply absorbed demand. None of the panic-selling sessions of November/December 2025 made the top-spike list because by then the 50-day baseline had already inflated.

Realized volatility sits at 27.9% — above the 10-year median of 23.0% and within touching distance of the 80th-percentile threshold of 29.5%. The market is pricing a wider risk band than usual, consistent with the de-rating event still being digested.

Institutional liquidity panel

The headline contradiction: the manifest carries an is_illiquid flag, but the underlying data shows a healthy mid-cap profile — £19M average daily turnover, 100% annual share-count turnover, zero blank sessions in the last 60 days, and a 1.5% median intraday range. The flag is triggered by a methodology rule (5-day capacity falls below the 0.5%-of-market-cap reporting tier), not by genuine market thinness.

A. ADV and turnover

B. Fund-capacity table

How much fund AUM can put on a position cleanly within five trading days, by participation rate and target portfolio weight:

C. Liquidation runway

Days required to fully exit a hypothetical issuer-level position, assuming a single-fund holder participating at 10% or 20% of ADV:

D. Execution friction

The 60-day median daily price range is 1.5% — squarely in the normal band for a UK mid-cap, well below the 2% threshold that would flag elevated impact cost. Volume coverage was 100% across the same window with zero blank sessions.

Bottom line on size: a fund can lift up to ~£19M in 5 sessions at 20% ADV without becoming the market — that supports a 5% position for AUM up to ~£380M. Larger funds (£1B+) building meaningful weight should plan a multi-week book-building program at 10% ADV, where 5-day capacity drops to £9.5M but execution prints look benign. Liquidity is not the binding constraint here.

Technical scorecard and stance

Stance — bearish on a 3-to-6 month horizon. The trend is decisively broken, distribution volume confirmed the de-rating, and the 8-week base near 470–500p has not yet produced a reclaim of any meaningful resistance. The Numbers tab describes a business growing operating profit at 7–8% — and the tape is rejecting that story aggressively, which means either the market is mispricing earnings durability or the consensus growth forecast is too high. Until the tape settles that question, technicals say wait.

Two specific levels that change the view:

• Above 545p (clears the 100-day SMA at 519p plus the late-October 2025 distribution shelf) — flips the stance to neutral and opens a path to retest the 200-day at 645p. A weekly close above 545p with volume above the 50-day average is the trigger.
• Below 447p (52-week low) — confirms the bearish next leg, with 380–400p (pre-COVID consolidation) as the next plausible support.

Implementation: liquidity is not the constraint. A patient fund can build or exit at institutional size; the question is whether, not how. For now, the technical action is watchlist — do not initiate ahead of either trigger. If a position must be held, the sub-447p stop is the only defensible invalidation level.